Casirivimab/Imdevimab

Preferred Label : Casirivimab/Imdevimab;

NCIt synonyms : REGN10933/REGN10987; REGN10933 REGN10987; REGN10933 Plus REGN10987; Anti-Spike SARS-CoV-2 Monoclonal Antibodies REGN-COV2; Anti-COVID Cocktail REGN-COV2; SARS-CoV-2-specific Antibodies REGN10933 and REGN10987; Casirivimab Imdevimab; Casirivimab and Imdevimab; Casirivimab Plus Imdevimab;

NCIt related terms : Monoclonal antibodies against SARS-CoV-2: casirivimab/imdevimab;

NCIt definition : A combination of two monoclonal antibodies, casirivimab and imdevimab, directed against the spike protein (SP) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), that can potentially be used for immunization against COVID-19. Upon administration, casirivimab and imdevimab specifically target and bind to non-overlapping regions of the receptor-binding domain (RBD) of SP, thereby blocking viral attachment and entry into human cells and may thereby neutralize SARS-CoV-2. This may slow the progression of the disease and accelerate recovery, and may potentially provide temporary protection against infection with SARS-CoV-2. Binding to two distinct regions of the RBD of SP may decrease the potential for virus escape mutants that occur upon treatment with a single SARS-CoV-2 antibody, and may provide enhanced protection against loss of efficacy.;

Drug name : REGEN-COV;

Molecule name : REGN COV2; REGN-COV2;

NCI Metathesaurus CUI : CL1656919;

Details

Origin ID

C173743;

UMLS CUI

C5433281;

CISMeF manual mappings
- casirivimab and imdevimab drug combination [MeSH Supplementary Concept]
- casirivimab and imdevimab drug combination [MeSH concept]
Currated CISMeF NLP mapping
- Product containing casirivimab and imdevimab (medicinal product) [SNOMED CT concept]
See also inter- (CISMeF)
- COVID-19 [MeSH Descriptor]
Semantic type(s)
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Product containing casirivimab and imdevimab (medicinal product) [SNOMED CT concept]
- casirivimab and imdevimab [ATC Code]
- casirivimab and imdevimab drug combination [MeSH Supplementary Concept]
Validated automatic mappings to BTNT
- casirivimab and imdevimab [ATC Code]
chemical_or_drug_has_mechanism_of_action
- Antigen Binding [NCIt concept]
concept_is_in_subset
- ACC/AHA COVID-19 Appendix Variables [NCIt concept]
- ACC/AHA Cardiovascular and Noncardiovascular Complications of COVID-19 Terminology [NCIt concept]
- Appendix 8: Pharmacological Therapy Terminology [NCIt concept]
- CTRP Agent Terminology [NCIt concept]
- CTRP Terminology [NCIt concept]
- NCI Drug Dictionary Terminology [NCIt concept]
- NCIt COVID-19 Agent Terminology [NCIt concept]
- NCIt COVID-19 Terminology [NCIt concept]
- Therapies for COVID-19 Terminology [NCIt concept]
has_target
- SARS-CoV-2 Spike Glycoprotein [NCIt concept]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients